Merck (MRK) Current Taxes (2009 - 2026)
Merck (MRK) reported Current Taxes of $3.9 billion for Q1 2026, down 23.84% year-over-year from $5.2 billion in Q1 2025, and down 16.5% on a QoQ basis from $4.7 billion in Q4 2025.
Merck (MRK) has 18 years of Current Taxes data on file, last reported at $3.9 billion in Q1 2026.
- Quarterly Current Taxes fell 23.84% year-over-year to $3.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 billion (down 23.84% YoY) and the FY2025 annual result came in at $4.7 billion, up 20.75% from the prior year.
- Current Taxes slipped to $3.9 billion in Q1 2026 per MRK's latest filing, from $4.7 billion in the prior quarter.
- Across five years, Current Taxes topped out at $5.2 billion in Q1 2025 and bottomed at $1.4 billion in Q2 2022.
- The 5-year median for Current Taxes is $2.6 billion (2023), against an average of $3.0 billion.
- The widest annual swing landed in 2024, when Current Taxes surged 118.58%; it then retreated 23.84% in 2026.
- Tracing MRK's Current Taxes over 5 years: stood at $2.0 billion in 2022, then surged by 33.38% to $2.6 billion in 2023, then soared by 47.75% to $3.9 billion in 2024, then increased by 20.75% to $4.7 billion in 2025, then retreated by 16.5% to $3.9 billion in 2026.
- Per Business Quant, the three latest MRK Current Taxes figures stand at $3.9 billion (Q1 2026), $4.7 billion (Q4 2025), and $4.8 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 1.09 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | - |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 3.95 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | - |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 3.13 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | - |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 662.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.95 Bn |
| Dec 31, 2025 | 4.73 Bn |
| Sep 30, 2025 | 4.85 Bn |
| Jun 30, 2025 | 4.16 Bn |
| Mar 31, 2025 | 5.18 Bn |
| Dec 31, 2024 | 3.91 Bn |
| Sep 30, 2024 | 4.33 Bn |
| Jun 30, 2024 | 2.78 Bn |
| Mar 31, 2024 | 2.40 Bn |
| Dec 31, 2023 | 2.65 Bn |
| Sep 30, 2023 | 1.98 Bn |
| Jun 30, 2023 | 1.49 Bn |
| Mar 31, 2023 | 1.87 Bn |
| Dec 31, 2022 | 1.99 Bn |
| Sep 30, 2022 | 1.70 Bn |
| Jun 30, 2022 | 1.44 Bn |
| Mar 31, 2022 | 1.57 Bn |
| Dec 31, 2021 | 1.22 Bn |
| Sep 30, 2021 | 954.00 Mn |
| Jun 30, 2021 | 971.00 Mn |
| Mar 31, 2021 | 1.49 Bn |
| Dec 31, 2020 | 1.60 Bn |
| Sep 30, 2020 | 984.00 Mn |
| Jun 30, 2020 | 1.27 Bn |
| Mar 31, 2020 | 1.03 Bn |
| Dec 31, 2019 | 736.00 Mn |
| Sep 30, 2019 | 873.00 Mn |
| Jun 30, 2019 | 634.00 Mn |
| Mar 31, 2019 | 807.00 Mn |
| Dec 31, 2018 | 1.97 Bn |
| Sep 30, 2018 | 759.00 Mn |
| Jun 30, 2018 | 661.00 Mn |
| Mar 31, 2018 | 717.00 Mn |
| Dec 31, 2017 | 708.00 Mn |
| Sep 30, 2017 | 396.00 Mn |
| Jun 30, 2017 | 1.98 Bn |
| Mar 31, 2017 | 2.33 Bn |
| Dec 31, 2016 | 2.24 Bn |
| Sep 30, 2016 | 1.21 Bn |
| Jun 30, 2016 | 1.21 Bn |
| Mar 31, 2016 | 1.86 Bn |
| Dec 31, 2015 | 1.56 Bn |
| Sep 30, 2015 | 2.12 Bn |
| Jun 30, 2015 | 1.88 Bn |
| Mar 31, 2015 | 2.45 Bn |
| Dec 31, 2014 | 1.24 Bn |
| Sep 30, 2014 | 2.47 Bn |
| Jun 30, 2014 | 192.00 Mn |
| Mar 31, 2014 | 595.00 Mn |
| Dec 31, 2013 | 251.00 Mn |
| Sep 30, 2013 | 1.30 Bn |
| Jun 30, 2013 | 409.00 Mn |
| Dec 31, 2012 | 1.20 Bn |
| Jun 30, 2012 | 1.09 Bn |
| Mar 31, 2012 | 1.19 Bn |
| Dec 31, 2011 | 781.00 Mn |
| Sep 30, 2011 | 1.46 Bn |
| Jun 30, 2011 | 1.17 Bn |
| Mar 31, 2011 | 1.33 Bn |
| Dec 31, 2010 | 1.24 Bn |
| Sep 30, 2010 | 1.63 Bn |
| Jun 30, 2010 | 879.40 Mn |
| Mar 31, 2010 | 723.00 Mn |
| Dec 31, 2009 | 1.17 Bn |
| Sep 30, 2009 | 232.00 Mn |
| Jun 30, 2009 | 202.00 Mn |